Pfizer, Inc. (PFE) Holdings Increased by First National Bank of Mount Dora Trust Investment Services

First National Bank of Mount Dora Trust Investment Services grew its stake in shares of Pfizer, Inc. (NYSE:PFE) by 32.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 125,065 shares of the biopharmaceutical company’s stock after buying an additional 30,650 shares during the quarter. Pfizer comprises 2.2% of First National Bank of Mount Dora Trust Investment Services’ holdings, making the stock its 20th biggest position. First National Bank of Mount Dora Trust Investment Services’ holdings in Pfizer were worth $4,201,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the business. West Oak Capital LLC grew its stake in shares of Pfizer by 4.5% in the 2nd quarter. West Oak Capital LLC now owns 24,566 shares of the biopharmaceutical company’s stock worth $825,000 after purchasing an additional 1,061 shares during the last quarter. First PREMIER Bank grew its stake in shares of Pfizer by 7.2% in the 2nd quarter. First PREMIER Bank now owns 70,339 shares of the biopharmaceutical company’s stock worth $2,362,000 after purchasing an additional 4,702 shares during the last quarter. Copper Rock Capital Partners LLC grew its stake in shares of Pfizer by 96.2% in the 2nd quarter. Copper Rock Capital Partners LLC now owns 13,223 shares of the biopharmaceutical company’s stock worth $429,000 after purchasing an additional 6,483 shares during the last quarter. DnB Asset Management AS grew its stake in shares of Pfizer by 2.9% in the 2nd quarter. DnB Asset Management AS now owns 922,148 shares of the biopharmaceutical company’s stock worth $30,975,000 after purchasing an additional 26,300 shares during the last quarter. Finally, McQueen Ball & Associates Inc. grew its stake in shares of Pfizer by 1.1% in the 2nd quarter. McQueen Ball & Associates Inc. now owns 57,878 shares of the biopharmaceutical company’s stock worth $1,944,000 after purchasing an additional 624 shares during the last quarter. Institutional investors own 69.09% of the company’s stock.

Shares of Pfizer, Inc. (PFE) traded down 1.04% on Friday, reaching $35.36. 28,871,059 shares of the company were exchanged. The stock has a market capitalization of $210.30 billion, a P/E ratio of 25.87 and a beta of 1.00. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $35.84. The stock has a 50 day moving average price of $33.64 and a 200-day moving average price of $33.53.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the prior year, the business earned $0.64 EPS. Pfizer’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, equities analysts expect that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were paid a dividend of $0.32 per share. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.62%. Pfizer’s payout ratio is 94.12%.

Several equities analysts have recently issued reports on PFE shares. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, July 10th. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, July 17th. UBS AG reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a research note on Monday, July 31st. BMO Capital Markets reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Pfizer in a research note on Wednesday, September 6th. Finally, ValuEngine cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. Pfizer currently has a consensus rating of “Hold” and an average price target of $37.72.

In related news, insider Sally Susman sold 38,230 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the sale, the insider now directly owns 124,774 shares of the company’s stock, valued at $4,242,316. The disclosure for this sale can be found here. Over the last three months, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/09/16/pfizer-inc-pfe-holdings-increased-by-first-national-bank-of-mount-dora-trust-investment-services.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply